Homozygous Familial Hypercholesterolemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | AstraZeneca, Arrowhead Pharma, Sanofi, Innovent Biologics

Posted on
by

Homozygous Familial Hypercholesterolemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | AstraZeneca, Arrowhead Pharma, Sanofi, Innovent Biologics
DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

 

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: 

  • The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108.23 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • There were almost 2,845 diagnosed prevalent cases of HoFHin the 7MM in total in 2022. According to the report, the number of these instances would rise by 2032 at a CAGR of 0.3% from 2019 to 2032
  • It was projected that there were 1,349 diagnosed prevalent cases of HoFH in the United States. Throughout the study period (2019–2032), an increase in these instances is anticipated by 2032
  • About 38% of all diagnosed prevalent cases of HoFH among the 7MM were from the EU4 and the UK; this percentage is anticipated to rise during the research period
  • About 1,214 cases of HoFH resulting from LDLR gene mutations were reported in 2022. These were followed by 67 cases of APOB, 54 cases of other mutations (LDLRAP1, APOE, SREBP2, STAP1), and 13 cases of PCSK9 gene mutation in the US. According to DelveInsight’s estimations, these are anticipated to rise between 2023 and 2032
  • Due to mutations in the LDLR gene, there were approximately 289 cases of HoFH in Japan in 2022. These were followed by 89 cases of additional mutations (LDLRAP1, APOE, SREBP2, STAP1), 24 cases of PCSK9, and 12 cases of APOB. A decline in instances is predicted by 2032.
  • Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharmaceutical, Arrowhead Pharma, Sanofi, Innovent Biologics, Cerenis Therapeutics, The Medicines Company, AstraZeneca, Akeso, Kastle Therapeutics, Organon and Co, NeuroBo Pharma, and others
  • Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Evinacumab, ARO-ANG 3 Injection, Alirocumab, IBI306, CER-001, ALN-PCSSC, AK102, Rosuvastatin 20mg, ISIS 301012, Atorvastatin, Gemcabene, and others
  • The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

 

Homozygous Familial Hypercholesterolemia Overview

HoFH is a serious hereditary condition that is rare and affects the metabolism of cholesterol. Mutations in both copies of the LDLR gene, which codes for the low-density lipoprotein receptor, or in other genes linked to cholesterol metabolism, like the APOB or PCSK9 genes, cause this hereditary illness.

 

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Report 

https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market

 

Homozygous Familial Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:

The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Homozygous Familial Hypercholesterolemia
  • Prevalent Cases of Homozygous Familial Hypercholesterolemia by severity
  • Gender-specific Prevalence of Homozygous Familial Hypercholesterolemia
  • Diagnosed Cases of Episodic and Chronic Homozygous Familial Hypercholesterolemia

 

Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast

 

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Homozygous Familial Hypercholesterolemia Therapies and Key Companies

  • ARO-ANG3: Arrowhead Pharmaceutical
  • LEQVIO (inclisiran/KJX839): Novartis/ Alnylam Pharmaceutical
  • Lerodalcibep (LIB003): LIB Therapeutics
  • Lomitapide: Amryt Pharma
  • Evinacumab: Ultragenyx Pharmaceutical
  • ARO-ANG 3 Injection: Arrowhead Pharma
  • Alirocumab: Sanofi
  • IBI306: Innovent Biologics
  • CER-001: Cerenis Therapeutics
  • ALN-PCSSC: The Medicines Company
  • AK102: Akeso
  • Rosuvastatin 20mg: AstraZeneca
  • ISIS 301012: Kastle Therapeutics
  • Atorvastatin: Organon and Co
  • Gemcabene: NeuroBo Pharma

 

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Market

 

Homozygous Familial Hypercholesterolemia Market Strengths

  • The clarity in disease understanding and pathogenesis have driven the development of novel pharmacological options like PCSK9inhibitors, ANGPTL3 inhibitor, and MTP inhibitor.
  • Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

 

Homozygous Familial Hypercholesterolemia Market Opportunities

  • Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
  • Advancements in healthcare technologies and digital health solutions can potentially enhance the early detection and personalized management of HoFH.

 

Scope of the Homozygous Familial Hypercholesterolemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharmaceutical, Arrowhead Pharma, Sanofi, Innovent Biologics, Cerenis Therapeutics, The Medicines Company, AstraZeneca, Akeso, Kastle Therapeutics, Organon and Co, NeuroBo Pharma, and others
  • Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Evinacumab, ARO-ANG 3 Injection, Alirocumab, IBI306, CER-001, ALN-PCSSC, AK102, Rosuvastatin 20mg, ISIS 301012, Atorvastatin, Gemcabene, and others
  • Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
  • Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Homozygous Familial Hypercholesterolemia Unmet Needs, KOL’s views, Analyst’s views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement 

 

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Homozygous Familial Hypercholesterolemia Market Report Introduction

2. Executive Summary for Homozygous Familial Hypercholesterolemia

3. SWOT analysis of Homozygous Familial Hypercholesterolemia

4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance

5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance

6. Homozygous Familial Hypercholesterolemia Disease Background and Overview

7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia 

9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices

10. Homozygous Familial Hypercholesterolemia Unmet Needs

11. Homozygous Familial Hypercholesterolemia Emerging Therapies

12. Homozygous Familial Hypercholesterolemia Market Outlook

13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2019–2032)

14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies

15. Homozygous Familial Hypercholesterolemia Market Drivers

16. Homozygous Familial Hypercholesterolemia Market Barriers

17.  Homozygous Familial Hypercholesterolemia Appendix

18. Homozygous Familial Hypercholesterolemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services